The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
=== Measuring vitamin status === Plasma concentrations of niacin and niacin metabolites are not useful markers of niacin status. Urinary excretion of the methylated metabolite N1-methyl-nicotinamide is considered reliable and sensitive. The measurement requires a 24-hour urine collection. For adults, a value of less than 5.8 μmol/day represent deficient niacin status and 5.8 to 17.5 μmol/day represents low. According to the World Health Organization, an alternative mean of expressing urinary N1-methyl-nicotinamide is as mg/g creatinine in a 24-hour urine collection, with deficient defined as <0.5, low 0.5-1.59, acceptable 1.6-4.29, and high >4.3 Niacin deficiency occurs before the signs and symptoms of pellagra appear. Erythrocyte nicotinamide adenine dinucleotide (NAD) concentrations potentially provide another sensitive indicator of niacin depletion, although definitions of deficient, low and adequate have not been established. Lastly, plasma tryptophan decreases on a low niacin diet because tryptophan converts to nicotinic acid mononucleotide (NaMN) and then to NAD by the kynurenine pathway. However, low tryptophan could also be caused by a diet low in this essential amino acid, so it is not specific to confirming vitamin status.
=== Feminist collages === In February 2019, she began posting collages which featured brief feminist slogans in public spaces across France, particularly in Paris and Marseille. Her collages are composed of black letters painted one by one on white sheets. Her first slogan was "Since I was 13, men have commented on my physical appearance in the street."
== Behavior == Not much is known about N. christyi. However, it is believed to be active by day and night. It is a semi-aquatic snake which spends much of its time in the water. An excellent swimmer. It tends to hide amongst rocks, in holes or overhanging tree roots at the shore line. It also makes use of any man-made structures such as bridges and jetties to hide. Generally this is not an aggressive snake, so bites are rare. If approached in water it will swim away swiftly. If threatened on land it will rear up, spread its narrow hood and hiss. It may strike if it's provoked extensively.
Sources: en.wikipedia.org
von Hagens, Gunther (March 1986). Heidelberg plastination folder: collection of technical leaflets of plastination. Heidelberg: Biodur Products. OCLC 256499636. First published as von Hagens, Gunther (1985). Heidelberger Plastinationshefter Sammlung von Merkblättern zur Plastination (in German). Heidelberg: University of Heidelberg. OCLC 174501422. da Fonseca, Liselotte Hermes; Thomas Kliche (2007). "Verführerische Leichen – verbotener Verfall. "Körperwelten" als gesellschaftliches Schlüsselereignis. Perspektiven Politischer Psychologie". Deutsches Ärzteblatt (in German). 104 (38). von Hagens, Gunther; Klaus Tiedemann; Wilhelm Kriz (March 1987). "The current potential of plastination". Anatomy and Embryology. 175 (4): 411–21. doi:10.1007/BF00309677. PMID 3555158. S2CID 21077765. Whalley, Angelina (2005). Pushing the Limits: Encounters with Body Worlds Creator Gunther von Hagens. Heidelberg: Arts & Sciences. ISBN 978-3-937256-07-8. OCLC 61119531. von Hagens, Gunther (2006). Body Worlds: The Anatomical Exhibition of Real Human Bodies. Heidelberg: Institute für Plastination. ISBN 978-3-937256-04-7. OCLC 69257041. Ottone NE et al. (2015). New contributions to the development of a plastination technique at room temperature with silicone. Anatomical Science International 2015; 90(2):126–35. doi:10.1007/s12565-014-0258-6 Ottone NE et al. (2018). E12 sheet plastination: Techniques and applications. Clinical Anatomy, 31(5):742–756. doi:10.1002/ca.23008 Ottone NE et al. (2020). Extraction of DNA from plastinated tissues. Forensic Science International, 309:110199.
Gavin Christopher Newsom (born October 10, 1967) is an American politician and businessman serving since 2019 as the 40th governor of California. A member of the Democratic Party, he served from 2011 to 2019 as the 49th lieutenant governor of California and from 2004 to 2011 as the 42nd mayor of San Francisco. Born and raised in San Francisco, Newsom graduated from Santa Clara University in 1989 with a Bachelor of Science in political science. Afterward, he founded the boutique winery PlumpJack Group in Oakville, California, with billionaire heir and family friend Gordon Getty as an investor. The company grew to manage 23 businesses, including wineries, restaurants, and hotels. Newsom began his political career in 1996, when San Francisco mayor Willie Brown appointed him to the city's Parking and Traffic Commission. Brown then appointed Newsom to fill a vacancy on the Board of Supervisors the next year and Newsom was first elected to the board in 1998. Newsom was elected mayor of San Francisco in 2003 and reelected in 2007. He was elected lieutenant governor of California in 2010 and reelected in 2014. As lieutenant governor, Newsom hosted The Gavin Newsom Show from 2012 to 2013 and in 2013 wrote the book Citizenville, which focuses on using digital tools for democratic change. Newsom was elected governor in 2018 and reelected in 2022. He faced criticism for his personal behavior and leadership style during the COVID-19 pandemic, which contributed to an unsuccessful recall effort in 2021.
=== Aquaporin-1 === Aquaporin-1 (Aqp1) from the human red blood cell has been solved by electron crystallography to 3.8 Å resolution (PDB: 1FQY). The aqueous pathway is lined with conserved hydrophobic residues that permit rapid water transport. Water selectivity is due to a constriction of the inner pore diameter to about 3 Å over the span of a single residue, superficially similar to that in the glycerol facilitator of E. coli. Several other more recently resolved crystal structures are available in RCSB, including but not limited to: PDB: 4CSK, 1H6I, 1IH5.
Sources: en.wikipedia.org
== Autoimmune diseases == In rheumatoid arthritis and other autoimmune diseases, such as psoriatic arthritis, systemic lupus erythematosus and Sjögren's syndrome, autoantibodies often attack citrullinated proteins. The presence of anti-citrullinated protein antibody is a standard test for rheumatoid arthritis, and it is associated with more severe disease. Citrullinated proteins are also found in the cellular debris accompanying the destruction of cells in Alzheimer's disease, and after smoking cigarettes. So citrullination seems to be part of the mechanism that stimulates the immune system in autoimmune disease. However, citrullinated proteins can also be found in healthy colon mucosa.
In general USPTO rejections on the sole grounds of the invention's being "inoperative" are rare, since such rejections need to demonstrate "proof of total incapacity", and cases where those rejections are upheld in a Federal Court are even rarer: nevertheless, in 2000, a rejection of a cold fusion patent was appealed in a Federal Court and it was upheld, in part on the grounds that the inventor was unable to establish the utility of the invention. A U.S. patent might still be granted when given a different name to disassociate it from cold fusion, though this strategy has had little success in the US: the same claims that need to be patented can identify it with cold fusion, and most of these patents cannot avoid mentioning Fleischmann and Pons' research due to legal constraints, thus alerting the patent reviewer that it is a cold-fusion-related patent. David Voss said in 1999 that some patents that closely resemble cold fusion processes, and that use materials used in cold fusion, have been granted by the USPTO. The inventor of three such patents had his applications initially rejected when they were reviewed by experts in nuclear science; but then he rewrote the patents to focus more on the electrochemical parts so they would be reviewed instead by experts in electrochemistry, who approved them. When asked about the resemblance to cold fusion, the patent holder said that it used nuclear processes involving "new nuclear physics" unrelated to cold fusion.
=== Mechanical properties === Crystalline cellulose has a stiffness about 140–220 GPa, comparable with that of Kevlar and better than that of glass fiber, both of which are used commercially to reinforce plastics. Films made from nanocellulose have high strength (over 200 MPa), high stiffness (around 20 GPa) but lack of high strain (12%). Its strength/weight ratio is 8 times that of stainless steel. Fibers made from nanocellulose have high strength (up to 1.57 GPa) and stiffness (up to 86 GPa).
At the time of the Miller–Urey experiment, Harold Urey was a Professor of Chemistry at the University of Chicago who had a well-renowned career, including receiving the Nobel Prize in Chemistry in 1934 for his isolation of deuterium and leading efforts to use gaseous diffusion for uranium isotope enrichment in support of the Manhattan Project. In 1952, Urey postulated that the high temperatures and energies associated with large impacts in Earth's early history would have provided an atmosphere of methane (CH4), water (H2O), ammonia (NH3), and hydrogen (H2), creating the reducing environment necessary for the Oparin-Haldane "primordial soup" scenario. Stanley Miller arrived at the University of Chicago in 1951 to pursue a PhD under nuclear physicist Edward Teller, another prominent figure in the Manhattan Project. Miller began to work on how different chemical elements were formed in the early universe, but, after a year of minimal progress, Teller was to leave for California to establish Lawrence Livermore National Laboratory and further nuclear weapons research. Miller, having seen Urey lecture on his 1952 paper, approached him about the possibility of a prebiotic synthesis experiment. While Urey initially discouraged Miller, he agreed to allow Miller to try for a year. By February 1953, Miller had mailed a manuscript as sole author reporting the results of his experiment to Science.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.